2026-04-05T10:42:07Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/111932025-10-24T10:56:16Zcom_2072_451667com_2072_378040col_2072_451668

Blood Hemoglobin Substantially Modulates the Impact of Gender, Morbid Obesity, and Hyperglycemia on COVID-19 Death Risk: A Multicenter Study in Italy and Spain MAYNERIS-PERXACHS, JORDI Russo, Maria Francesca de Hollanda, Ana Armengou Arxé, Arola Rottoli, Matteo Arnoriaga Rodríguez, María Comas-Cufí, Marc Fages, Ester de Genover Gil, Ariadna Castro Guardiola, Antoni Fernández-Real, Jose Manuel Ramos , Rafel COVID-19 (Malaltia) - Epidemiologia Hemoglobina Hiperglucèmia Obesitat mòrbida DISEASES::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections Other subheadings::Other subheadings::Other subheadings::/epidemiology CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Hemoglobins::Hemoglobin A DISEASES::Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Hyperglycemia DISEASES::Nutritional and Metabolic Diseases::Nutrition Disorders::Overnutrition::Obesity::Obesity, Morbid ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus Otros calificadores::Otros calificadores::Otros calificadores::/epidemiología COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::hemoglobinas::hemoglobina A ENFERMEDADES::enfermedades nutricionales y metabólicas::enfermedades metabólicas::trastornos del metabolismo de la glucosa::hiperglucemia ENFERMEDADES::enfermedades nutricionales y metabólicas::trastornos nutricionales::hipernutrición::obesidad::obesidad mórbida Covid-19; Hemoglobina; Hiperglucèmia; Obesitat mòrbida Covid-19; Hemoglobina; Hiperglucemia; Obesidad mórbida Covid-19; Hemoglobin; Hyperglycemia; Morbid obesity Background: Hyperglycemia and obesity are associated with a worse prognosis in subjects with COVID-19 independently. Their interaction as well as the potential modulating effects of additional confounding factors is poorly known. Therefore, we aimed to identify and evaluate confounding factors affecting the prognostic value of obesity and hyperglycemia in relation to mortality and admission to the intensive care unit (ICU) due to COVID-19. Methods: Consecutive patients admitted in two Hospitals from Italy (Bologna and Rome) and three from Spain (Barcelona and Girona) as well as subjects from Primary Health Care centers. Mortality from COVID-19 and risk for ICU admission were evaluated using logistic regression analyses and machine learning (ML) algorithms. Results: As expected, among 3,065 consecutive patients, both obesity and hyperglycemia were independent predictors of ICU admission. A ML variable selection strategy confirmed these results and identified hyperglycemia, blood hemoglobin and serum bilirubin associated with increased mortality risk. In subjects with blood hemoglobin levels above the median, hyperglycemic and morbidly obese subjects had increased mortality risk than normoglycemic individuals or non-obese subjects. However, no differences were observed among individuals with hemoglobin levels below the median. This was particularly evident in men: those with severe hyperglycemia and hemoglobin concentrations above the median had 30 times increased mortality risk compared with men without hyperglycemia. Importantly, the protective effect of female sex was lost in subjects with increased hemoglobin levels. Conclusions: Blood hemoglobin substantially modulates the influence of hyperglycemia on increased mortality risk in patients with COVID-19. Monitoring hemoglobin concentrations seem of utmost importance in the clinical settings to help clinicians in the identification of patients at increased death risk. We thank CERCA Programme/Generalitat de Catalunya for institutional support. This study was in part supported by the Spanish Plan Nacional de I+D+i 2013‐2016 and the Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0001) ‐ co-financed by European Development Regional Fund “A way to achieve Europe”, Operative Programme Intelligent Growth 2014‐2020. CIBERobn is an initiative of ISCIII. Partially supported by FIS Grant (PI17/01167), ISCIII. JM-P is funded by the Miguel Servet Program from the Instituto de Salud Carlos III (ISCIII CP18/00009), co-funded by the European Social Fund “Investing in your future” 2025-10-24T10:56:16Z 2025-10-24T10:56:16Z 2024-03-14T11:26:59Z 2024-03-14T11:26:59Z 2021-11-02 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://hdl.handle.net/11351/11193 Frontiers in Endocrinology;12 https://doi.org/10.3389/fendo.2021.741248 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess Frontiers Media Scientia